Targeting the hallmarks of ovarian cancer: The big picture

Camilla Nero, Anna Fagotti, Giovanni Scambia, Marco Petrillo, Giulia Amadio, Daniela Gallo Guido

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective As a result of relevant achievements in the field of translational research, several active drugs and multiple biological targets are available in ovarian cancer (OC). In this complex scenario, there is an urgent need to effectively summarize the available data in order to update conclusions, and outline perspectives. Methods The results in terms of target identification and drug development have been summarized using the well-known hallmarks of cancer firstly described, and recently modified by Hanahan and Weinberg [1-2]. Published data from clinical trials have been retrieved from PubMed, Embase, CINAHL and Cochrane database. Ongoing clinical trials were searched using clinicaltrials.gov web platform, and identified using NCT number. Results Genomic instability and angiogenesis are the most actively investigated hallmarks in high-grade serous OC, and the inhibition of tumor immune evasion appears as the emerging strategy for molecularly-driven therapy. Targeting sustained proliferative signaling through MEK and mTOR inhibitors seems the most promising approach in clear cell, and low-grade serous OC. Conclusions This substantial amount of data suggests that targeted therapies are already part of the clinical and therapeutic management of OC patients. The expectations of getting from translational research a better knowledge of tumor biology and therefore personalized drugs are high and worthy of maximum effort from referral centers.
Original languageEnglish
Pages (from-to)176-183
Number of pages8
JournalGynecologic Oncology
Volume142
DOIs
Publication statusPublished - 2016

Keywords

  • Cancer hallmarks
  • Epithelial ovarian cancer
  • Molecular pathways
  • Obstetrics and Gynecology
  • Oncology

Fingerprint

Dive into the research topics of 'Targeting the hallmarks of ovarian cancer: The big picture'. Together they form a unique fingerprint.

Cite this